Company intelligence / Profile preview
Debiopharm
Lausanne, Vaud, Switzerlanddebiopharm.com ↗
- Ownership
- Private
- Employees
- ~400
- Development stage
- Commercial
01
Overview
Debiopharm has developed two blockbuster therapies - oxaliplatin for colorectal cancer and triptorelin for prostate cancer and central precocious puberty. They also have a potential third blockbuster drug for Head & Neck Cancer currently in phase III development[3].
- Therapeutic areas
- Women's HealthOncologyEndocrinologyInfectious Diseases
- Modalities
- Small moleculesbiologics
- Industry
- Biotech
02
Drug pipeline
44 assets43 more assets in the full pipeline.
03
Partnerships
Ipsen Pharma (for Decapeptyl/triptorelin)Allergan (former partner for Trelstar)Ubiquigent Limited
Beyond the preview
Go deeper on Debiopharm.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Debiopharm.